  Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.; ; et al in Osteoporosis International (2012), 23 This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is ... [more ▼] This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. INTRODUCTION: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. METHODS: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (</=3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. RESULTS: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients </=74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. CONCLUSIONS: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients. [less ▲] Detailed reference viewed: 14 (4 ULg)Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.; ; et al in BONE (2012), 50 BACKGROUND: We studied 265 men (mean age 56.4years; range 18-83years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate ... [more ▼] BACKGROUND: We studied 265 men (mean age 56.4years; range 18-83years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177). METHODS: Patients received either a single ZOL 5mg infusion or RIS 5mg oral daily at randomization, along with calcium (1000mg) and vitamin D (400-1200IU). Primary endpoint: difference in percentage change from baseline in bone mineral density (BMD) at the lumbar spine (LS) at 12months. Secondary endpoints: percentage changes in BMD at total hip (TH) and femoral neck (FN), relative changes in bone turnover markers (beta-CTx and P1NP), and overall safety. FINDINGS: In the treatment subpopulation, ZOL increased LS BMD by 4.7% vs. 3.3% for RIS and at TH the percentage changes were 1.8% vs. 0.2%, respectively. In the prevention subpopulation, bone loss was prevented by both treatments. At LS the percentage changes were 2.5% vs. -0.2% for ZOL vs. RIS and at TH the percentage changes were 1.1% vs. -0.4%, respectively. ZOL significantly increased lumbar spine BMD more than RIS at Month 12 in both the prevention population (p=0.0024) and the treatment subpopulation (p=0.0232) in men. In the treatment subpopulation, ZOL demonstrated a significantly greater reduction in serum beta-CTx and P1NP relative to RIS at all time-points. In the prevention subpopulation, ZOL significantly reduced beta-CTx at all time-points, and P1NP at Month 3 (p=0.0297) only. Both treatments were well tolerated in men, albeit with a higher incidence of influenza-like illness and pyrexia events post-infusion with ZOL. INTERPRETATION: Once-yearly ZOL preserves or increases BMD within 1year to a greater extent than daily RIS in men receiving glucocorticoid therapy. [less ▲] Detailed reference viewed: 16 (3 ULg)Effectiveness of zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis in men and premenopausal women; ; et al in Arthritis and Rheumatism (2010, October), 62(10), 902-903 Detailed reference viewed: 145 (1 ULg)Bisphosphonates and glucocorticoid osteoporosis in men : results of a randomized controlled trial comparing zoledronic acid with risedronate; ; et al in Osteoporosis International (2010, May), 21(Suppl.1), 19 Detailed reference viewed: 25 (1 ULg)Effect of single annual infusion of zoledronic acid on bone turnover markers versus daily oral risedronate in patients with glucocorticoid-induced osteoporosis; ; et al in Osteoporosis International (2009, April), 20(Suppl.1), 128-129 Detailed reference viewed: 9 (4 ULg)Effect on single annual infusion of zoledronic acid (5mg) on lumbar spine bone mineral density versus daily oral risedronate (5mg) in subgroups of patients receiving glucocorticoid therapy.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 7-8 Detailed reference viewed: 7 (1 ULg)Effect of a single i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis.; ; Reginster, Jean-Yves  et alin Bone (2009) Detailed reference viewed: 8 (1 ULg) A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis; ; et al in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 56 Detailed reference viewed: 10 (2 ULg)A single infusion of zoledronic acid 5 mg (ZOL) is significantly more effective than daily oral risedronate 5 mg (RIS) in increasing bone mineral density (BMD) of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (GIO); ; et al in Osteoporosis International (2008, April), 19(Suppl.1), 23-24 Detailed reference viewed: 16 (1 ULg)Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis; ; Reginster, Jean-Yves et alin Osteoporosis International (2008), 19(S2), 376 Detailed reference viewed: 6 (1 ULg)Une perfusion d'acide zolédronique 5 mg est plus efficace que le risédronate 5 mg/j per os sur l'augmentation de la densité lombaire et fémorale au cours de l'ostéoporose cortisonique; ; et al in Revue du Rhumatisme (2008), 75 Detailed reference viewed: 14 (5 ULg)Effets d'une perfusion unique d'acide zolédronique 5 mg versus risédronate (5 mg/jour) sur le remodelage osseux sur 1 an chez des patients avec ostéroporose cortisonique; ; et al in Revue du Rhumatisme (2008), 75 Detailed reference viewed: 6 (2 ULg)Effect of zoledronic acid (single 5 mg infusion) on lumbar spine bone mineral density versus oral risedronate (5 mg/day) over one year in subgroups of patients receiving glucocorticoid therapy; ; et al in Osteoporosis International (2008), 19(S2), 248-249 Detailed reference viewed: 9 (2 ULg) |
||
